News and Updates

Researchers identify key mechanisms of resistance to the RAS inhibitor daraxonrasib, paving the way for new, highly effective combination cancer therapies.

Discover how next-gen B-cell depletion therapies are reshaping CNS autoimmune research and setting a new gold standard for regulatory approval processes.

Tenax Therapeutics releases Phase 3 LEVEL trial data for TNX-103 in PH-HFpEF patients. Discover the key clinical outcomes for this potential new therapy.

New dosimetry data for Radspherin offers a breakthrough in treating peritoneal metastases, highlighting the potential of targeted alpha-emitter therapy.

Kodiak Sciences has started its Phase 3 ALTO trial for KSI-501. Discover how this bispecific drug aims to transform Diabetic Macular Edema treatment.

Sionna Therapeutics reports that its CF drug SION-719 failed to meet primary sweat chloride endpoints in a recent study. Read the latest clinical update here.

Haleon partners with Singapore’s A*STAR to launch a clinical study investigating metabolic health markers, aiming to improve wellness for Asian women.

City of Hope is transforming oncology research by decentralizing clinical trials. Discover how their new model improves equitable access to cancer care.

Sionna Therapeutics halts its SION-109 CF trial after failing to meet key endpoints, cementing Vertex Pharmaceuticals' lead in the cystic fibrosis market.

Discover the latest in pharma: RevMed and BeOne form a strategic Asian clinical trial partnership, while MoonLake celebrates a successful Phase 3 result.